Gene Therapy Clinical Trials
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme (GBM), gynecological cancers, and renal cell carcinoma (RCC) who are receiving antiangiogenesis treatment.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: 18F-fludeoxyglucose (18F-FDG)
- drug: 18F-FPPRGD2
Eligibility
Inclusion Criteria:
- Provides written informed consent
- Diagnosed with advanced NSCLC, breast cancer, GBM or other cancers (such as head and
neck, colorectal, pancreatic, renal cancers); patients will undergo anti-angiogenesis
treatment or treatment with other drugs that may alter angiogenesis
- Able to remain still for duration of each imaging procedure (about one hour)
Exclusion Criteria:
- Pregnant or nursing
- Contraindication to MRI
- History of renal insufficiency (only for MRI contrast administration)
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061
Not Recruiting